NetworkNewsBreaks – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) Closes $50M Follow-On
Matinas BioPharma Holdings (NYSE American: MTNB), a clinical-stage biopharmaceutical company, recently closed its $50 million follow-on. The underwritten public offering consisted of 32,260,000 shares of the company’s common stock that were sold at a public offering price of $1.55 per share, therefore resulting in gross proceeds of roughly $50 million to Matinas BioPharma. The company also granted the underwriters a 30-day option to acquire up to an additional 4,839,000 shares to cover any overallotments in connection with the offering. ROTH Capital Partners served as co-manager for the offering. To view the full press release, visit http://nnw.fm/7vFGS About Matinas BioPharma Matinas…







